Literature DB >> 12389465

What's your real cost of capital?

James J McNulty1, Tony D Yeh, William S Schulze, Michael H Lubatkin.   

Abstract

In valuing any investment project or corporate acquisition, executives must decide what discount rate to use in their estimates of future cash flows. The traditional approach is to apply the capital asset pricing model (CAPM), which has remained fundamentally unchanged for 40 years. But the formula--in particular, its beta element--has long been a source of frustration. In fact, corporate executives and investment bankers routinely fudge their CAPM estimates, say the authors, because experience and intuition tell them the model produces inappropriate discount rates. CAPM has three main problems: First, beta is a measure of both a stock's correlation and its volatility; second, beta is based on historical data; and third, CAPM rates don't take into account the term of the investment. These factors together result in discount rates that defy common sense. As an alternative to CAPM and its beta element, the authors developed a forward-looking approach to calculating a company's cost of capital, the market-derived capital pricing model (MCPM). It does not incorporate any measure of historical stock-to-market correlation, relying instead on estimates of future volatility derived from the options market. This is helpful since investor expectations from the options market are built into a company's current stock price. Using GE as an example, the authors give step-by-step instructions for how to calculate discount rates with MCPM. They also offer evidence from a range of industries to show that MCPM's discount rates are more realistic--especially from the corporate investor's perspective--than are CAPM's.

Mesh:

Year:  2002        PMID: 12389465

Source DB:  PubMed          Journal:  Harv Bus Rev        ISSN: 0017-8012


  2 in total

1.  Impact of alternative medical device approval processes on costs and health.

Authors:  Benjamin P George; Vinayak Venkataraman; E Ray Dorsey; S Claiborne Johnston
Journal:  Clin Transl Sci       Date:  2014-09-03       Impact factor: 4.689

Review 2.  Evaluation of the Clinical, Technical, and Financial Aspects of Cost-Effectiveness Analysis of Artificial Intelligence in Medicine: Scoping Review and Framework of Analysis.

Authors:  Jesus Gomez Rossi; Ben Feldberg; Joachim Krois; Falk Schwendicke
Journal:  JMIR Med Inform       Date:  2022-08-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.